References
1. Bieber T. Atopic dermatitis. N Engl J Med 2008;358:1483–94.
2. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006;118(1):152–169.
3. DaVeiga SP. Epidemiology of atopic dermatitis: a review. Allergy Asthma Proc 2012;33(3):227–234.
4. Ständer S, Luger TA. Itch in atopic dermatitis–pathophysiology and treatment. Acta Dermatovenerol Croat 2010;18(4):289–296.
5. Klein PA, Clark RAF. An Evidence-Based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999;135(12):1522–1525.
6. Sher L, Chang J, Patel B, Balkrishnan R, Fleischer AB. Relieving the Pruritus of Atopic Dermatitis: A Meta-analysis. Value Health 2012;15(4):A249–A250.
7. Sohn KH, Lee JG, Jee SY. A philological study on demonstration of atopic dermatitis. J East-West Med 2009;34(4):15–24.
8. Min DL, Park EJ, Kang KH. Review of Clinical and Experimental Studies on External Application Treatment for Atopic Dermatitis in the Korean Literature. J Pediatr Korean Med 2013;27(1):36–49.
9. Park BK, Chang GT, Kim JH. A study of external treatments for the atopic dermatitis. J Korean Orient Pediatr 2003;17(1):71–86.
10. Wu YL. Bonchojongsin First editionth ed. Seoul: Haeng Lim Publishers Co; 1982. p. 143.
11. Heo J. Newly translated Donguibogam Second editionth ed. Seoul: Bubin Publishers Co; 2009. p. 797–810.
12. Lee KS, Jeong ES, Heo SH, Seo JH, Jeong DG, Choi YK. A Novel Model for Human Atopic Dermatitis: Application of Repeated DNCB Patch in BALB/c Mice, in Comparison with NC/Nga Mice. Lab Anim 2010;26(1):95–102.
13. Kabashima K. New concept of the pathogenesis of atopic dermatitis: Interplay among the barrier, allergy, and pruritus as a trinity. J Invest Dermatol 2013;70:3–11.
14. Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009;129(8):1892–1908.
15. Ye YM, Kim BE, Shin YS, Park HS, Leung DYM. Overexpression of Epidermal Filaggrin in Patients with Chronic Idiopathic Urticaria Correlates with Urticaria Severity. J Allergy Clin Immunol 2013;131(2):AB56.
16. Koblenzer CS. Itching and the atopic skin. J Allergy Clin Immunol 1999;104(3):S109–S113.
17. Gupta MA, Gupta AK. Depression modulates pruritus perception. A study of pruritus in psoriasis, atopic dermatitis and chronic idiopathic urticaria. Ann N Y Acad Sci 1999;885:394–395.
18. Shim WH, Song CH, Park HJ, Kim HS, Chin HW, Kim SH, et al. Clinical characteristics of itch in patients with adult and childhood atopic dermatitis. Korean J Dermatol 2011;49(4):318–327.
19. Park SW, Yan YP, Satriotomo I, Vemuganti R, Dempsey RJ. Substance P is a promoter of adult neural progenitor cell proliferation under normal and ischemic conditions. J. Neurosurg 2007;107(3):593–599.
20. Donkin JJ, Turner RJ, Hassan I, Vink R. Substance P in traumatic brain injury. Prog Brain Res 2007;161:97–109.
21. Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids 2006;31(3):251–272.
22. Yamaoka J, Kawana S. Rapid changes in substance P signaling and neutral endopeptidase induced by skin-scratching stimulation in mice. J Dermatol Sci 2007;48(2):123–132.
23. Hon KLE, Lam MCA, Wong KY, Leung TF, Ng PC. Pathophysiology of Nocturnal Scratching in Childhood Atopic Dermatitis: The Role of Brain-Derived Neurotrophic Factor and Substance P. Br J Dermatol 2007;157(5):922–925.
24. Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol 2002;147(1):71–79.
25. Mosmann TR, Coffmann RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989;46:111–139.
26. Ogawa H, Mukai K, Kawano Y, Minegishi Y, Karasuyama H. Th2-inducing cytokines IL-4 and IL-33 synergistically elicit the expression of transmembrane TNF-α on macrophages through the autocrine action of IL-6. Biochem Biophys Res Commun 2012;420(1):114–118.
27. Werner S, Krieg T, Smola H. Keratinocyte-fibroblast interactions in wound healing. J Invest Dermatol 2007;127(5):998–1008.
28. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007;8(1):49–62.
29. Bonizzi G, Karin M. The two NF-κ B activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25(6):280–288.
30. Monaco C, Andreakos E, Kiriakidis S, Mauri C, Bicknell C, Foxwell B, et al. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA 2004;101(15):5634–5639.
31. Arbabi S, Maier RV. Mitogen-activated protein kinases. Crit Care Med 2002;30(1):S74–S79.
32. Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 1999;11(2):211–218.
33. Hong ZY, Xiao M, Yang Y, Han ZQ, Cao Y, Li CR, et al. Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation. Carcinogenesis 2011;32(10):1550–1558.
34. Liu J, Lu Y, Wu Q, Goyer RA, Waalkes MP. Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite. J Pharmacol Exp Ther 2008;326:363–368.
35. Wester RC, Hui X, Barbadillo S, Maibach HI, Lowney YW, Schoof RA, et al. In Vivo Percutaneous Absorption of Arsenic from Water and CCA-Treated Wood Residue. Toxicol Sci 2004;79(2):287–295.